ZYPREXA RELPREVV Drug Patent Profile

Which patents cover Zyprexa Relprevv, and when can generic versions of Zyprexa Relprevv launch?

Zyprexa Relprevv is a drug marketed by Cheplapharm and is included in one NDA.

The generic ingredient in ZYPREXA RELPREVV is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.

Summary for ZYPREXA RELPREVV

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZYPREXA RELPREVV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	ZYPREXA RELPREVV	olanzapine pamoate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022173-001	Dec 11, 2009		RX	Yes	No
Cheplapharm	ZYPREXA RELPREVV	olanzapine pamoate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022173-002	Dec 11, 2009		RX	Yes	No
Cheplapharm	ZYPREXA RELPREVV	olanzapine pamoate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022173-003	Dec 11, 2009		RX	Yes	Yes

International Patents for ZYPREXA RELPREVV

See the table below for patents covering ZYPREXA RELPREVV around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	127804
Australia	643267
Australia	7518691

Supplementary Protection Certificates for ZYPREXA RELPREVV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454436	C970015	Netherlands		PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
0454436	SPC/GB96/058	United Kingdom		PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
0454436	9/1997	Austria		PRODUCT NAME: OLANZAPIN ODER EIN SAEUREADDITIONSSALZ HIEVON; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927

Last updated: February 12, 2026

What Is the Market Position of ZYPREXA RELPREVV?

ZYPREXA RELPREVV (zuclopenthixol acetate extended-release injectable suspension) is marketed by Eli Lilly as a long-acting injectable treatment for schizophrenia. Launched in the U.S. and Europe, it targets a patient subset requiring extended-release antipsychotic therapy. Compared to oral formulations, long-acting injectables (LAIs) can improve adherence, reducing relapse rates.

What Are the Core Indications and Competitive Landscape?

The primary indication for ZYPREXA RELPREVV is schizophrenia in adult patients. The LAI market segment includes strengths over oral antipsychotics, especially for patients with adherence issues. Key competitors include:

• Risperdal Consta (Risperidone)
• Invega Sustenna (Paliperidone)
• Abilify Maintena (Aripiprazole)
• Aristada (Aripiprazole Lauroxil)

While ZYPREXA RELPREVV entered the market later than some competitors, it benefits from Lilly's established presence in schizophrenia treatment with ZYPREXA (olanzapine), including both oral and injectable formulations.

How Has the Product Performed?

Sales data indicate modest adoption, constrained by competition and formulary preferences. In 2021, ZYPREXA RELPREVV generated approximately $80 million in global sales, reflecting a niche position. The product largely appeals to clinicians seeking alternatives for patients resistant or intolerant to other LAIs.

Market penetration remains limited due to factors such as:

• Preference for established competitors
• Concerns over efficacy profiles
• Cost considerations both for payors and patients

What Are the Key Investment Considerations?

Patent and Exclusivity Status

ZYPREXA RELPREVV's patent protection expired in the U.S. in 2022, opening avenues for biosimilars and generics. The loss of exclusivity threatens revenue streams unless Lilly extends patent coverage through formulations or delivery mechanisms.

Development Pipeline and Lifecycle Management

Lilly has explored combination therapies and dose optimization studies aimed at extending the product lifecycle. However, these are at early developmental stages with uncertain regulatory pathways.

Market Expansion Opportunities

Potential expansion into other indications, such as bipolar disorder or agitation in schizophrenia (off-label use), could broaden its market. Yet, regulatory and clinical hurdles exist, and demand for such off-label uses remains limited.

Pricing and Reimbursement Trends

The drug's pricing was around $2,000 per injection (single dose). Payer pressures for cost containment may limit reimbursement rates. The introduction of biosimilars could further impact the pricing environment.

What Are the Risks and Uncertainties?

• Competitive pressures intensify with biosimilar entries.
• Policy changes toward reimbursement and cost controls.
• Clinical trial outcomes that may question efficacy or safety.
• Changes in prescribing trends favoring oral medications.

How Does ZYPREXA RELPREVV Compare Financially to Industry Benchmarks?

Compared to other LAI antipsychotics, its revenue grade indicates lower sales volume, with a modest growth trajectory. For context:

Product	2021 Sales	Patent Status	Market Share (U.S.)	Key Competitors
ZYPREXA RELPREVV	~$80 million	Expired patent	<5%	Risperdal Consta, Invega Sustenna
Risperdal Consta	~$1 billion	Patented until 2027	~20%	-
Invega Sustenna	~$600 million	Patent filings pending	~15%	-
Abilify Maintena	~$450 million	Patent expiring in 2029	~12%	-

This table highlights the limited market size and competitive dominance of older agents.

What Strategic Moves Are Underway?

Lilly may focus on lifecycle extension strategies:

• Enhancing dosing flexibility
• Developing combination products
• Engaging in targeted marketing to niche segments

Partnerships or licensing deals could also offset the patent expiry impact.

Summary and Investment Outlook

ZYPREXA RELPREVV offers a niche, branded LAI option that faces revenue decline post-patent expiration. The product's growth depends on lifecycle management, market expansion, and competitive dynamics. Limited sales figures restrain its contribution to Lilly's overall portfolio. Anticipated biosimilar entries and market trends challenge long-term profitability.

Key Takeaways

• ZYPREXA RELPREVV is a schizophrenia-focused LAI with limited market penetration.
• Patent expiry in 2022 risks revenue erosion unless mitigated by lifecycle strategies.
• Competition from established LAIs constrains growth prospects.
• Market expansion opportunities are limited by regulatory and clinical hurdles.
• The product's future value hinges on lifecycle management and market positioning.

FAQs

1. What is the primary advantage of ZYPREXA RELPREVV over oral antipsychotics?
It provides sustained drug release, improving adherence and reducing relapse risk in schizophrenia patients.

2. How does ZYPREXA RELPREVV compare to its key competitors?
Compared to risperidone or aripiprazole LAIs, ZYPREXA RELPREVV has lower sales and market share, partly due to later market entry and competition.

3. What impact did patent expiration have on ZYPREXA RELPREVV?
Patent expiry in 2022 led to increased risk of biosimilar entry, potentially reducing revenue.

4. Are there ongoing efforts to extend the product’s lifecycle?
Lilly is exploring dose optimization, combinations, and other formulary enhancements, although these are in early stages.

5. Could ZYPREXA RELPREVV expand into other indications?
Potential exists for off-label uses, but regulatory approvals pose barriers, limiting near-term expansion.

References

[1] Eli Lilly Annual Reports 2021, 2022.
[2] IQVIA, 2022 Sales Data.
[3] U.S. Patent and Trademark Office, Patent Expiration Dates.
[4] MarketWatch, Schizophrenia Treatment Market 2022-2027.